July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The efficacy and safety of a novel posterior scleral reinforcement in the treatment of pathological myopia
Author Affiliations & Notes
  • Zequn Miao
    Department of Ophthalmology, Eye diseases and optometry Institute, Peking University People's Hospital, Beijing, China
  • Lejin Wang
    Department of Ophthalmology, Eye diseases and optometry Institute, Peking University People's Hospital, Beijing, China
  • Footnotes
    Commercial Relationships   Zequn Miao, None; Lejin Wang, None
  • Footnotes
    Support  The National Natural Science Fund of China
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zequn Miao, Lejin Wang; The efficacy and safety of a novel posterior scleral reinforcement in the treatment of pathological myopia. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5947.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the effects and safety of a novel posterior scleral reinforcement (PSR) in the treatment of pathological myopia.

Methods : This study included 34 highly myopic eyes of 19 patients who underwent a novel PSR. Axial length, refractive error, best corrected visual acuity (BCVA), macular scans and the incidence of complications were recorded at baseline and examined postoperatively at yearly intervals for three years.

Results : The mean value of axial elongation was 0.55±1.01mm over the 3 years, approximately 0.18mm per year, similar to the findings in normal schoolchildren(0.25 mm per year). There was no significant difference in refractive error before and after the surgery in the 3-years visit(P=0.548).The postoperative refractive error almost maintained stable with a mean change of +0.28±1.60D, during the 3 years after the surgery. Statistical results showed significant differences in best corrected visual acuity (BCVA) between the pre-operation and postoperative status during the 3 years(P=0.006). Among them, the BCVA improved in 29 eyes(82.86%), remained stable in 5 eyes(14.29%) and there were no records of visual decline in any postoperative patient. There were no serious complications during the 3 year follow-up period.

Conclusions : The novel PSR is a safe and effective treatment in controlling the pathological process of pathological myopia.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×